MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 315361 | Name: Doxercalciferol
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Doxercalciferol, also known as 1-hydroxy Vitamin D2, is a synthetic analog of vitamin D with potential antineoplastic activity. In the liver, doxercalciferol is converted to its biologically active vitamin D metabolites, which control the intestinal absorption of dietary calcium, the tubular reabsorption of calcium by the kidney and, in conjunction with parathyroid hormone (PTH), the mobilization of calcium from the skeleton. Through interaction with specific receptor proteins in target tissues, these vitamin D metabolites act directly on osteoblasts to stimulate skeletal growth, and on the parathyroid glands to suppress PTH synthesis and secretion.

Chemical Structure

Doxercalciferol
Doxercalciferol
CAS#54573-75-0

Theoretical Analysis

MedKoo Cat#: 315361

Name: Doxercalciferol

CAS#: 54573-75-0

Chemical Formula: C28H44O2

Exact Mass: 412.3341

Molecular Weight: 412.65

Elemental Analysis: C, 81.50; H, 10.75; O, 7.75

Price and Availability

Size Price Availability Quantity
25mg USD 250.00 2 Weeks
50mg USD 450.00 2 Weeks
100mg USD 750.00 2 Weeks
200mg USD 1,250.00 2 Weeks
500mg USD 2,550.00 2 Weeks
1g USD 3,850.00 2 Weeks
2g USD 6,450.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Doxercalciferol; 1-hydroxy Vitamin D2; Hectorol; 1-Hydroxyergocalciferol; TSA 840; TSA840; TSA-840;
IUPAC/Chemical Name
(1S,3R,Z)-5-((E)-2-((1S,3aR,7aS)-1-((2S,5S,E)-5,6-dimethylhept-3-en-2-yl)-7a-methylhexahydro-1H-inden-4(2H)-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol.
InChi Key
HKXBNHCUPKIYDM-UHICYICISA-N
InChi Code
InChI=1S/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11+,23-12-/t19-,20+,24+,25+,26-,27-,28+/m1/s1
SMILES Code
O[C@@H]1C[C@@H](O)C(/C(C1)=C\C=C2[C@@]3([H])CC[C@@H]([C@H](/C=C/[C@@H](C)C(C)C)C)[C@]3(C)CCC\2)=C
Appearance
White to yellow/brown solid powder.
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO.
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Doxercalciferol is a Vitamin D2 analog, acts as an activator of Vitamin D receptor, and prevents renal disease.
In vitro activity:
To further investigate the effects of paricalcitol and doxercalciferol on PTH mRNA expression, primary culture of pig parathyroid cells were treated with different concentrations of paricalcitol or the major active metabolite of doxercalciferol (1α, 25-(OH)2D2, active doxercalciferol). The results from real-time RT-PCR analysis showed that, in a similar manner of paricalcitol, active doxercalciferol suppressed PTH mRNA effectively in a dose-dependent manner achieving a 75% inhibition at 100 nM. Active doxercalciferol did not have a significant effect on VDR mRNA expression. Reference: Int J Endocrinol. 2010;2010:621687. https://pubmed.ncbi.nlm.nih.gov/20204178/
In vivo activity:
WT and Tg mice were subjected to to streptozotocin (STZ) treatment to induce diabetes. At this point the mice were treated with vehicle (V) (60:40 propylene glycol/H2O) or a low dose of vitamin D analog doxercalciferol (Dox) (30 ng/kg, injected intraperitoneally three times per week) for 16 weeks. Vehicle-treated WT mice developed robust progressive albuminuria during the 16 weeks, and the low dose Dox treatment had little effects on the development of albuminuria in WT mice. In contrast, baseline vehicle-treated Tg mice exhibited significantly reduced albuminuria compared with WT+V mice, and the low dose Dox almost completely blocked albuminuria in Tg mice without altering the blood glucose levels and body weight. Reference: J Am Soc Nephrol. 2012 Dec;23(12):1977-86. https://pubmed.ncbi.nlm.nih.gov/23123403/
Solvent mg/mL mM
Solubility
DMSO 66.5 161.15
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 412.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Duggal J, Harrison JS, Studzinski GP, Wang X. Involvement of microRNA181a in differentiation and cell cycle arrest induced by a plant-derived antioxidant carnosic acid and vitamin D analog doxercalciferol in human leukemia cells. Microrna. 2012;1(1):26-33. doi: 10.2174/2211536611201010026. PMID: 25048087. 2. Wu-Wong JR, Nakane M, Gagne GD, Brooks KA, Noonan WT. Comparison of the pharmacological effects of paricalcitol and doxercalciferol on the factors involved in mineral homeostasis. Int J Endocrinol. 2010;2010:621687. doi: 10.1155/2010/621687. Epub 2010 Mar 2. PMID: 20204178; PMCID: PMC2831199. 3. Li J, Li N, Yan S, Liu M, Sun B, Lu Y, Shao Y. Doxercalciferol Alleviates Bone Deteriorations and Cartilage Degeneration in Aging Mice. Exp Clin Endocrinol Diabetes. 2020 Aug;128(8):540-547. doi: 10.1055/a-0754-1956. Epub 2018 Oct 31. PMID: 30380573. 4. Wang Y, Deb DK, Zhang Z, Sun T, Liu W, Yoon D, Kong J, Chen Y, Chang A, Li YC. Vitamin D receptor signaling in podocytes protects against diabetic nephropathy. J Am Soc Nephrol. 2012 Dec;23(12):1977-86. doi: 10.1681/ASN.2012040383. Epub 2012 Nov 2. PMID: 23123403; PMCID: PMC3507366.
In vitro protocol:
1. Duggal J, Harrison JS, Studzinski GP, Wang X. Involvement of microRNA181a in differentiation and cell cycle arrest induced by a plant-derived antioxidant carnosic acid and vitamin D analog doxercalciferol in human leukemia cells. Microrna. 2012;1(1):26-33. doi: 10.2174/2211536611201010026. PMID: 25048087. 2. Wu-Wong JR, Nakane M, Gagne GD, Brooks KA, Noonan WT. Comparison of the pharmacological effects of paricalcitol and doxercalciferol on the factors involved in mineral homeostasis. Int J Endocrinol. 2010;2010:621687. doi: 10.1155/2010/621687. Epub 2010 Mar 2. PMID: 20204178; PMCID: PMC2831199.
In vivo protocol:
1. Li J, Li N, Yan S, Liu M, Sun B, Lu Y, Shao Y. Doxercalciferol Alleviates Bone Deteriorations and Cartilage Degeneration in Aging Mice. Exp Clin Endocrinol Diabetes. 2020 Aug;128(8):540-547. doi: 10.1055/a-0754-1956. Epub 2018 Oct 31. PMID: 30380573. 2. Wang Y, Deb DK, Zhang Z, Sun T, Liu W, Yoon D, Kong J, Chen Y, Chang A, Li YC. Vitamin D receptor signaling in podocytes protects against diabetic nephropathy. J Am Soc Nephrol. 2012 Dec;23(12):1977-86. doi: 10.1681/ASN.2012040383. Epub 2012 Nov 2. PMID: 23123403; PMCID: PMC3507366.
1: Dennis VC, Albertson GL. Doxercalciferol treatment of secondary hyperparathyroidism. Ann Pharmacother. 2006 Nov;40(11):1955-65. doi: 10.1345/aph.1G523. Epub 2006 Oct 24. PMID: 17062838. 2: Trump DL, Aragon-Ching JB. Vitamin D in prostate cancer. Asian J Androl. 2018 May-Jun;20(3):244-252. doi: 10.4103/aja.aja_14_18. PMID: 29667615; PMCID: PMC5952478. 3: Gembillo G, Siligato R, Amatruda M, Conti G, Santoro D. Vitamin D and Glomerulonephritis. Medicina (Kaunas). 2021 Feb 22;57(2):186. doi: 10.3390/medicina57020186. PMID: 33671780; PMCID: PMC7926883. 4: Li J, Li N, Yan S, Liu M, Sun B, Lu Y, Shao Y. Doxercalciferol Alleviates Bone Deteriorations and Cartilage Degeneration in Aging Mice. Exp Clin Endocrinol Diabetes. 2020 Aug;128(8):540-547. doi: 10.1055/a-0754-1956. Epub 2018 Oct 31. PMID: 30380573. 5: Coburn JW, Maung HM, Elangovan L, Germain MJ, Lindberg JS, Sprague SM, Williams ME, Bishop CW. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis. 2004 May;43(5):877-90. doi: 10.1053/j.ajkd.2004.01.012. PMID: 15112179. 6: Choi JH, Ke Q, Bae S, Lee JY, Kim YJ, Kim UK, Arbeeny C, Thadhani R, Kang PM. Doxercalciferol, a pro-hormone of vitamin D, prevents the development of cardiac hypertrophy in rats. J Card Fail. 2011 Dec;17(12):1051-8. doi: 10.1016/j.cardfail.2011.08.006. Epub 2011 Sep 9. PMID: 22123370; PMCID: PMC3226953. 7: Kubodera N. A new look at the most successful prodrugs for active vitamin D (D hormone): alfacalcidol and doxercalciferol. Molecules. 2009 Sep 29;14(10):3869-80. doi: 10.3390/molecules14103869. PMID: 19924035; PMCID: PMC6254965. 8: Kant KS, Gonzalez AR, Hariachar S, Bernardo M, Duggal A, Engstrand S, Hunter J, Plone M, Hertel J. Converting to doxercalciferol capsules from intravenous paricalcitol or doxercalciferol. J Ren Nutr. 2012 Jan;22(1):34-40.e2. doi: 10.1053/j.jrn.2011.02.004. Epub 2011 Jun 11. PMID: 21652220. 9: Ray K. Doxercalciferol is as effective as calcitriol for the treatment of secondary hyperparathyroidism in CKD. Nat Rev Nephrol. 2010 Dec;6(12):692. doi: 10.1038/nrneph.2010.149. PMID: 21155068. 10: Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr. 2008 Aug;88(2):582S-586S. doi: 10.1093/ajcn/88.2.582S. PMID: 18689406. 11: New drug overview. Doxercalciferol. Am J Health Syst Pharm. 1999 Dec 1;56(23):2410-1. doi: 10.1093/ajhp/56.23.2410. PMID: 10595800. 12: Liu Y, Shin DY, Oh S, Kim S, Koh Y, Kim I. KML001 and doxercalciferol induce synergistic antileukemic effect in acute lymphoid leukemia cells. Oncol Rep. 2017 Jul;38(1):481-487. doi: 10.3892/or.2017.5688. Epub 2017 Jun 1. PMID: 28586017. 13: Park J, Rhee CM, Lau WL, Kalantar-Zadeh K. Clinical uses of 1-alpha-hydroxy- ergocalciferol. Curr Vasc Pharmacol. 2014 Mar;12(2):306-12. doi: 10.2174/15701611113119990025. PMID: 23713877. 14: Simonzadeh N, Ronsen B, Upadhyaya S, Wilkinson E, Kanesvaran K, Patel V, Bendale P. Determination of degradation products of doxercalciferol by solid- phase extraction and reversed-phase HPLC. J Chromatogr Sci. 2014 Jul;52(6):520-5. doi: 10.1093/chromsci/bmt073. Epub 2013 Jun 18. PMID: 23780943. 15: Fadem SZ, Al-Saghir F, Zollner G, Swan S. Converting hemodialysis patients from intravenous paricalcitol to intravenous doxercalciferol - a dose equivalency and titration study. Clin Nephrol. 2008 Oct;70(4):319-24. doi: 10.5414/cnp70319. PMID: 18826857. 16: St-Arnaud R, Arabian A, Akhouayri O, Knutson JC, Strugnell SA. Differential effects of oral doxercalciferol (Hectorol) or paricalcitol (Zemplar) in the Cyp27b1-null mouse model of uremia. Nephron Exp Nephrol. 2011;119(3):e67-74. doi: 10.1159/000329663. Epub 2011 Aug 18. PMID: 21849802. 17: Mazzaferro S, Goldsmith D, Larsson TE, Massy ZA, Cozzolino M. Vitamin D metabolites and/or analogs: which D for which patient? Curr Vasc Pharmacol. 2014 Mar;12(2):339-49. doi: 10.2174/15701611113119990024. PMID: 23713876. 18: Dheerendra PC, Sakhuja V, Kohli HS, Jha V. Efficacy and safety of oral doxercalciferol in the management of secondary hyperparathyroidism in chronic kidney disease stage 4. Indian J Nephrol. 2013 Jul;23(4):271-5. doi: 10.4103/0971-4065.114492. PMID: 23960343; PMCID: PMC3741971. 19: Joist HE, Ahya SN, Giles K, Norwood K, Slatopolsky E, Coyne DW. Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients. Clin Nephrol. 2006 May;65(5):335-41. doi: 10.5414/cnp65335. PMID: 16724654. 20: Zisman AL, Ghantous W, Schinleber P, Roberts L, Sprague SM. Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol. Am J Nephrol. 2005 Nov-Dec;25(6):591-5. doi: 10.1159/000089707. Epub 2005 Nov 9. PMID: 16282676.